Skip to main content
SpringerLink
Log in

Evaluation of brain and whole-body pharmacokinetics of 11C-labeled diphenylhydantoin in rats by means of planar positron imaging system

  • Original Article
  • Published:
Annals of Nuclear Medicine Aims and scope Submit manuscript

Abstract

Objective

A planar positron imaging system (PPIS) enables whole-body dynamic imaging of radiopharmaceuticals labeled with positron-emitting nuclides. We evaluated the difference in the brain and whole-body pharmacokinetics of 11C-diphenylhydantoin (11C-DPH) between intravenous and duodenal administration in rats.

Methods

Male Wistar rats (8 weeks old, mean body weight 250 g) were examined under anesthesia. A tracer amount of 11C-DPH (2 μg or less; about 5 MBq) was injected into the tail vein (n = 3) or duodenum (n = 3). Immediately following the administration, PPIS scans were obtained for 20 min. Regions of interest (ROIs) were set on the brain, heart, liver, intestinal field, and urinary bladder, identified on the integrated images. The relative uptake value (RUV, %) was calculated as the regional count divided by the whole-body count multiplied by 100. Sequential changes in the RUV for each ROI were analyzed for the brain and other organs.

Results

Following intravenous injection of 11C-DPH, the RUV in the brain was 1.59 ± 0.07%, 1.53 ± 0.09%, 1.40 ± 0.09%, and 1.38 ± 0.08% at 5 min, 10 min, 15 min, and 20 min after the injection, respectively. After duodenal administration, the corresponding values were 0.54 ± 0.16%, 1.01 ± 0.12%, 1.43 ± 0.24%, and 1.52 ± 0.06%, respectively. The 11C-DPH distribution was significantly lower at 5 min and 10 min following duodenal administration than after intravenous injection (P < 0.01). Radioactivity in the urinary bladder was identified by 20 min after both intravenous injection and duodenal administration.

Conclusions

The present study demonstrated a difference in the brain distribution of 11C-DPH between intravenous and duodenal administration in rats. Use of the PPIS is feasible for the evaluation of the pharmacokinetics in both the target organ and the whole body in small animals.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Uchida H, Okamoto T, Ohmura T, Shimizu K, Satoh N, Koike T, et al. A compact planar positron imaging system. Nucl Instrum Methods Phys Res A 2004;A516:564–574.

    Article  Google Scholar 

  2. Tsukada H, Sato K, Fukumoto D, Nishiyama S, Harada N. Evaluation of d-isomers of O-11C-methyl tyrosine and O-18F-fluoromethyl tyrosine as tumor-imaging agents in tumor-bearing mice: comparison with l-and d-11C-methionine. J Nucl Med 2006;47:679–688.

    PubMed  CAS  Google Scholar 

  3. Alvin JD, Bush MT. Diphenylhydantoin and other hydantoins. In: Vida JA, editor. Anticonvulsivants. New York: Academic Press; 1977. p. 116.

    Google Scholar 

  4. Noach EL, Woodbury DM, Goodman LS. Studies on the absorption, distribution, fate and excretion of 4-C14-labeled diphenyhydantoin, J Pharmacol Exp Therap 1958;122:301–314.

    CAS  Google Scholar 

  5. Noach EL, Rees HV. Intestinal distribution of intravenously administered diphyenythydontoin in the rat. Arch Int Pharmacodyn 1964;150:52–61.

    PubMed  CAS  Google Scholar 

  6. Stavchansky SA, Tibury RS, McDonald JM, Ting CT, Kostenbauder HB. In vivo distribution of carbon-11 phenytoin and its major metabolite, and their use in scintigraphic imaging. J Nucl Med 1978;19:936–941.

    PubMed  CAS  Google Scholar 

  7. Baron JC, Roeda D, Murani C, Crouzel C, Chodkiewicz JP, Comar D. Brain regional pharmacokinetics of 11C-labeled diphenylhydantoin: positron emission tomography in humans. Neurology 1983;33:580–585.

    PubMed  CAS  Google Scholar 

  8. Roeda D, Crouzel C, Van Zanten B. The production of 11C-phosgene without added carrier. Radiochem Radioanal Lett 1978;33:175–178.

    CAS  Google Scholar 

  9. Roeda D, Westera G. The synthesis of some 11C-labelled anti-epileptic drugs with potential utility as radiopharmaceuticals: hydantoins and barbiturate. Int J Appl Radiat Isot 1981;32:843–845.

    Article  PubMed  CAS  Google Scholar 

  10. Kinobe RT, Parkinson OT, Mitchell DJ, Gillam EM. P450 2C18 catalyzes the metabolic bioactivation of phenytoin. Chem Res Toxicol 2005;18:1868–1875.

    Article  PubMed  CAS  Google Scholar 

  11. Yamazaki H, Komatsu T, Takemoto K, Saeki M, Minami Y, Kawaguchi Y, et al. Decreases in phenytoin hydroxylation activities catalyzed by liver microsomal cytochrome P450 enzymes in phenytoin-treated rats. Drug Metab Dispos 2001;29:427–434.

    PubMed  CAS  Google Scholar 

  12. Firemark H, Barlow CF, Roth LJ. The entry, accumulation and binding of diphenylhydantoin-2-C14 in brain. Int J Neuropharmacol 1963;2:25–38.

    Article  CAS  Google Scholar 

  13. Inaba T, Umeda T. Biliary excretion of diphenylhydantoin in the rat: time-course studies. Drug Metab Dispos 1975;3:69–73.

    PubMed  CAS  Google Scholar 

  14. A Monaem, EL-Hawari, Gabriel LPLAA. Role of the enterohepatic circulation in the elimination of phenytoin in the rat. Drug Metab Dispos 1978;6:59–69.

    Google Scholar 

  15. Suzuki T, Saito Y, Nishihara K. Kinetics of diphenylhydantoin disposition in man. Chem Pharm Bull 1970;18:405–411.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan

    Yukinori Hasegawa, Yasukazu Kanai, Shinji Hasegawa, Eku Shimosegawa & Jun Hatazawa

  2. Hamamatsu Photonics K.K., Hamamatsu, Japan

    Takashi Okamoto

  3. Nihon Medi-Physics Co. Ltd., Nishinomiya, Japan

    Tamiko Matsui

  4. Department of Pharmacology, Osaka University Graduate School of Medicine, Osaka, Japan

    Yoshihisa Kurachi

Authors
  1. Yukinori Hasegawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yasukazu Kanai
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shinji Hasegawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Takashi Okamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tamiko Matsui
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Eku Shimosegawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yoshihisa Kurachi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jun Hatazawa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jun Hatazawa.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hasegawa, Y., Kanai, Y., Hasegawa, S. et al. Evaluation of brain and whole-body pharmacokinetics of 11C-labeled diphenylhydantoin in rats by means of planar positron imaging system. Ann Nucl Med 22, 301–307 (2008). https://doi.org/10.1007/s12149-007-0111-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12149-007-0111-2

Keywords

Search

Navigation